Evidence map›Paper›PMID 42360572›Full record

ArticleBreast cancer research and treatment2026

Comments on: Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer.

Rajesh Prasad Jayaswal, Anuj Kumar Rana, Rama Kumari Badyal

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rajesh Prasad JayaswalDepartment of Medical Laboratory Science, University Institute of Allied Health Sciences, Chandigarh University, Mohali, Punjab, 140413, India. rpjayaswal.jec@gmail.com.ORCID http://orcid.org/0000-0001-7158-5630
Anuj Kumar RanaDepartment of Biotechnology, School of Applied and Life Sciences, Uttaranchal University, Dehradun, Uttarakhand, 248007, India.ORCID http://orcid.org/0009-0009-2167-928X
Rama Kumari BadyalDepartment of Pathology, Government Medical College/ Rajindra Hospital, Patiala, Punjab, 147001, India.ORCID http://orcid.org/0000-0002-7715-664X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DPYD genotyping before capecitabine therapy represents a clinically actionable pharmacogenomic strategy to reduce avoidable fluoropyrimidine-related toxicity in metastatic breast cancer. Commenting on the cost-effectiveness analysis by Chiddarwar, Blaes and Kuntz, this correspondence supports the authors' findings while extending the discussion from economic value to implementation readiness. We propose that DPYD testing should be evaluated through a globally transferable framework incorporating ancestry-aware variant coverage, rapid turnaround pathways, genotype-linked dose decision support, budget-impact assessment and real-world toxicity surveillance. Such an approach may help translate cost-effective pharmacogenomics into equitable, operationally feasible breast cancer care across diverse health systems.

Indexed as

Antimetabolites, AntineoplasticBreast NeoplasmsCapecitabineDihydrouracil Dehydrogenase (NADP)Cost-Benefit AnalysisCost-Effectiveness AnalysisFemaleGenotypeHumansNeoplasm MetastasisPharmacogeneticsAntimetabolites, AntineoplasticCapecitabineDihydrouracil Dehydrogenase (NADP)CapecitabineCost-effectivenessDPYD genotypingFluoropyrimidine toxicityImplementation justiceMetastatic breast cancerPharmacogenomicsPrecision oncology

Identifiers

PMID42360572

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.